Pipeline
Learn more about our R&D pipeline and ongoing trials below
Development Programs – Solid Tumor
Drug
Indication
Phase 1
Phase 2
Phase 3
BGB-24714 (SMAC Mimetic) +/- Chemotherapy
Advanced solid tumors
BGB-3245
(BRAF inhibitor)
Advanced solid tumors with BRAF mutations
BGB-26808 (HPK1 inhibitor) +/- Tislelizumab (anti-PD-1)
Advanced solid tumors
BGB-30813
(DGKζ inhibitor) +/- Tislelizumab
Advanced or metastatic solid tumors
BGB-A3055 (anti-CCR8) +/- Tislelizumab
Select advanced or metastatic solid tumors
BGB-B167 (CEA-4-1BB bispecific antibody) +/- Tislelizumab
Advanced solid tumors
BGB-B167 +/- Tislelizumab
Advanced or metastatic solid tumors
BGB-A445 (anti-OX40) +/- Tislelizumab
Select advanced solid tumors
Tislelizumab + BGB-A445
Advanced solid tumors
BGB-A445 +/- Tislelizumab +/- Sitravatinib (mulitkinase inhibitor) +/- BGB-15025 (HPK1 inhibitor) +/- Chemotherapy
NSCLC after anti-PD-(L)1 therapy
LBL-007 (anti-LAG-3) +/- Tislelizumab + Bevacizumab + Capecitabine*
Maintenance in unresectable or metastatic MSS/mismatch repair proficient CRC
LBL-007 + Tislelizumab + Chemotherapy*
1L unresectable locally advanced or metastatic ESCC
Lifirafenib (RAF inhibitor) + Mirdametinib
(MEK inhibitor)†
Advanced solid tumors
Ociperlimab (anti-TIGIT) + Tislelizumab
1L PD-L1 high advanced NSCLC
2L PD-L1+ advanced ESCC
2L + cervical cancer
Advanced solid tumors
Ociperlimab + Tislelizumab + BAT1706
(anti-VEGF)
1L HCC
Ociperlimab + Tislelizumab + Chemotherapy
1L NSCLC
Ociperlimab + Tislelizumab + Concurrent Chemoradiotherapy
Previously untreated, stage III unresectable NSCLC
Pamiparib
(PARP 1/2 inhibitor)
2L/3L maintenance platinum-sensitive OC
Tislelizumab
1L HCC
2L/3L NSCLC
Neoadjuvant MSI-high or dMMR CRC
Previously treated advanced MSI-high or dMMR solid tumors
Tislelizumab +/- Surzebiclimab (anti-TIM-3) +/- LBL-007*
Advanced solid tumors
Tislelizumab +/- Surzebiclimab +/- LBL-007*
1L recurrent or metastatic HNSCC
Tislelizumab +/- Ociperlimab +/- LBL-007*
Resectable stage II/IIIA NSCLC
Tislelizumab +/- BGB-A445 +/- LBL-007 +/- Chemotherapy*
1L advanced, unresectable, or metastatic NSCLC
Tislelizumab + BGB-10188
(PI3Kδ inhibitor)
Advanced solid tumors
Tislelizumab + BGB-15025
(HPK1 inhibitor)
Advanced solid tumors
Tislelizumab + Chemoradiotherapy
Localized ESCC
Tislelizumab + Chemotherapy/ Chemoradiotherapy
Resectable ESCC
Tislelizumab + Chemotherapy
1L advanced ESCC
1L GC/GEJC
Resectable stage II or IIIA NSCLC
1L advanced nasopharyngeal cancer
1L advanced UBC
1L ES-SCLC
Tislelizumab + DKN-01 (anti-DKK1) + Chemotherapy**
1L/2L GC/GEJC
Tislelizumab + Fruquintinib
(VEGFR inhibitor)‡
Advanced GC/GEJC, CRC, and NSCLC
Advanced triple negative BC, EC, and CRC
Tislelizumab + Lenvatinib
(VEGFR kinase inhibitor)
1L HCC
Advanced solid tumors
Tislelizumab + Sitravatinib
(multikinase inhibitor)
Advanced NSCLC after anti-PD-(L)1 therapy
Advanced ESCC after anti-PD-(L)1 therapy
Tislelizumab + Surufatinib
(VEGFR, FGFR, CSF-1R inhibitor)‡
Advanced solid tumors
Zanidatamab
(anti-HER2 bispecific antibody)§
2L+ HER2+ BTC
Zanidatamab + Chemotherapy +/- Tislelizumab§
1L HER2+ BC and 1L HER2+ GC/GEJC
1L HER2+ advanced/metastatic GC/EC
Australia
Australia, China
Australia, China, US
Australia, New Zealand
Australia, US
China
China, S. Korea
China, Thailand
Coming Soon
United States
Worldwide
*In collaboration with Nanjing Leads Biolabs.
†In collaboration with SpringWorks Therapeutics.
**In collaboration with Leap Therapeutics, Inc.
‡ Clinical collaboration with Hutchison Medipharma International.
§ In collaboration with Zymeworks,Inc.
Safety and efficacy have not been established for investigational products and/or uses.
BC, breast cancer; BTC, biliary tract cancer; CRC, colorectal cancer; CSF-1R, colony stimulating factor-1 receptor; DKK1, Dickkopf-1; EC, endometrial cancer; ESCC, esophageal squamous cell carcinoma; ES-SCLC, extensive-stage small cell lung cancer; FGFR, fibroblast growth factor receptor; GC, gastric cancer; GEJC, gastroesophageal junction carcinoma; HCC, hepatocellular carcinoma; HER2, human epidermal growth factor receptor-2; NSCLC, non–small cell lung cancer; SCLC, small cell lung cancer; UBC, urothelial bladder cancer; VEGFR, vascular endothelial growth factor receptors.
Development Programs – Hematology
Drug
Indication
Phase 1
Phase 2
Phase 3
Tislelizumab
(anti-PD-1)
R/R cHL
R/R cHL
BGB-10188
(PI3Kδ inhibitor) +/- Zanubrutinib
B-cell malignancies
Sonrotoclax (Bcl-2 inhibitor) monotherapy
B-cell malignancies
R/R CLL/SLL
R/R MCL
Waldenstrom macroglobulinemia
Sonrotoclax + Azacitidine +/- Posaconazole
Myeloid malignancies
Sonrotoclax + Dexamethasone +/- Carfilzomib
R/R multiple myeloma with t(11;14)
Sonrotoclax + Zanubrutinib
B-cell malignancies
BGB-16673
(BTK-targeted CDAC)
B-cell malignancies
B-cell malignancies
Ociperlimab (anti-TIGIT) +/- Tislelizumab or Rituximab
R/R DLBCL
Zanubrutinib
R/R DLBCL with CD79B
Previously treated B-cell malignancies
B-cell malignancies
Zanubrutinib + Lenalidomide +/- Rituximab
R/R DLBCL
Zanubrutinib + Obinutuzumab
R/R FL
Zanubrutinib + Rituximab
1L MCL
R/R MZL
Australia, China
Australia, US
China
Japan
United States
Worldwide
Safety and efficacy have not been established for investigational products and/or uses.
CDAC, chimeric degradation activating compound; cHL, classical Hodgkin lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; PI3Kδ, phosphoinositide 3-kinase delta; R/R, recurrent/refractory; TIGIT, T-cell immunoreceptor with Ig and ITIM domains.
Interactive Clinical Pipeline
Videos
PARPI Mechanism of Action
Anti-PD-1 Mechanism of Action
BTKI Mechanism of Action
Anti-TIGIT Mechanism of Action
